Recap: Eagle Pharmaceuticals Q3 Earnings - Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals EGRX reported its Q3 earnings results on Monday, November 7, 2022 at 06:50 AM.

Here's what investors need to know about the announcement.

Eagle Pharmaceuticals beat estimated earnings by 23.08%, reporting an EPS of $1.12 versus an estimate of $0.91.

Revenue was up $26.05 million from the same period last year.

Last quarter the company missed on EPS by $1.8 which was followed by a 5.05% drop in the share price the next day.

Here's a look at Eagle Pharmaceuticals's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	3.36	3.88	0.94	0.83
EPS Actual	1.56	4.04	0.85	0.56
Revenue Estimate	116.89M	123.33M	51.08M	46.40M
Revenue Actual	74.14M	115.87M	42.32M	39.85M

To track all earnings releases for Eagle Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.